The Ninth Annual American Association for Cancer Research International Conference on Frontiers in Cancer Prevention Research

Abstract

The Ninth Annual AACR Frontiers in Cancer Prevention Research conference was held in Philadelphia in November 7–10, 2010. Its thematic focus was “Prevention: From Basic Science to Public Health Benefit.” Telomere plasticity, the microenvironment, inflammation, transformation to the metastatic phenotype, and pathways to obesity were highlighted as important elements of carcinogenesis amenable to intervention. The integration of information from novel technologies related to physical biology, molecular and genetic profiles, and imaging along with behavioral and clinical parameters have advanced risk stratification and early detection. Cancer prevention represents a powerful testing ground for the development of individually tailored intervention and for increasing the efficiency of drug discovery. Advances in clinical trials relate to more efficient design strategies, have shown first-in-human targeting capabilities, and have developed powerful strategies to overcome accrual barriers. Tailored intervention strategies now show high efficacy on large cohorts across several cancer types. These successes are expected to increase.

The frequency and disribution of cancer cases in Hatay District in 2008

“…Gelişmiş laboratuar, görüntüleme metotları ve toplumda giderek yaygınlaşan tarama çalışma-larıyla kanserler daha erken safhalarda saptanabilmektedir. 17 Kanserlerin risk faktörleri arasında aile öyküsü vardır. Bizim yaptığımız çalışmaya göre olguların %60,4'ünde aile öyküsü yok, %24.1'inde aile öy-küsü mevcut, %15.5'inde aile öyküsü bilinmiyor.…”

Primäre Krebsprävention

“…Die Literatur [14] zu korrelativen als auch kausalen Zusammenhängen hinsichtlich einer Risikoerhöhung, an verschiedenen Krebsarten bei krankhaftem Übergewicht zu erkranken, ist so evident, dass krankhaftes Übergewicht -gemessen am BMI oder auch direkt am Bauchoder Hüftumfang -wichtige Zielgrößen in jedem primären Präventionsprogramm sein müssen [15,16]. Die Diskussion, dass das krankhafte Übergewicht ein erkannter Risikofaktor ist, ist abgeschlossen.…”

Recruitment strategy cost and impact on minority accrual to a breast cancer prevention trial

“…Cancer prevention trials typically have lower participation rates compared to therapeutic trials, relating to the fact that healthy study volunteers, or those at increased risk for cancer, perceive less tangible gains from volunteering compared to those with established cancer [14]. Combined with the challenges of minority recruitment, cancer prevention trials must expend additional resources and utilize careful recruitment planning in order to successfully accrue minorities [2,9].…”